Combining energy-based focal ablation and immune checkpoint inhibitors: preclinical research and clinical trials.

ABSTRACT: Energy-based focal therapy (FT) uses targeted, minimally invasive procedures to destroy tumors while preserving normal tissue and function. There is strong emerging interest in understanding how systemic immunity against the tumor can occur with cancer immunotherapy, most notably immune checkpoint inhibitors (ICI). The motivation for combining FT and ICI in cancer management relies on the synergy between the two different therapies: FT complements ICI by reducing tumor burden, increasing objective response rate, and reducing side effects of ICI; ICI supplements FT by reducing local recurrence, controlling distal metastases, and providing long-term protection. This combinatorial strategy has shown promising results in preclinical study (since 2004) and the clinical trials (since 2011). Unde

SUBMITTER: Jiang M 

PROVIDER: S-EPMC10211342 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature